Barclays initiated coverage of Henry Schein (HSIC) with an Overweight rating and $86 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSIC:
- Henry Schein expands exclusive distribution partnership with vVARDIS
- Henry Schein price target raised to $90 from $83 at Evercore ISI
- Henry Schein price target raised to $79 from $78 at Barrington
- Henry Schein price target raised to $78 from $76 at JPMorgan
- Henry Schein Reports Strong Q3 2025 Earnings